In The Spotlight
STORM Therapeutics, the leading drug discovery company focused on small molecule therapies modulating RNA modifying enzymes, announced that it has raised an additional GBP4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd.
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners.
Idorsia Ltd announced that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy.
Biohaven Pharmaceutical Holding Company Ltd. and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. FDA has notified the Company that it may proceed with its clinical investigation of BHV-5000.
Adverum Biotechnologies, Inc , a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced the dosing of the first patient in the ADVANCE Phase 1/2 clinical trial of ADVM-043 for alpha-1 antitrypsin (A1AT) deficiency.
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type 1 diabetes (T1D), announced the completion of the final visit of the last patient included in its 12-month CHANGE-MS Phase 2b study evaluating GNbAC1 in relapsing-remitting multiple sclerosis (RRMS).
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.
Orchard Therapeutics , a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced the opening of a second facility for technical operations in the San Francisco Bay Area.
Recipharm, a leading contract development and manufacturing organisation (CDMO) and Kancera, a development company focused on cancer therapy, have signed a contract for the development and manufacture of the pharmaceutical candidate KAND567.
Serialization software provider SEA Vision and packaging machine manufacturer Marchesini Group have collaborated to launch a new data collection plug-in designed to improve efficiencies during pharmaceutical manufacturing.
PepsiCo has agreed to host an interactive session at the AIPIA Congress 2017, asking the Association’s members to come up with their very best ideas for new packaging formats for PepsiCo brands, incorporating all types of Active and Intelligent Packaging formats and technologies.
Recipharm, a leading contract development and manufacturing organisation (CDMO) has equipped its sixth facility with serialisation capabilities ahead of the US and European regulation enforcement deadlines.